Victory Capital Management
NTLA icon

Victory Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Victory Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Sell
15,291
-47,218
-76% -$661K ﹤0.01% 2205
2026
Q1 		$801K Sell
62,509
-12,658
-17% -$161K ﹤0.01% 1919
2025
Q4 		$676K Buy
75,167
+32,718
+77% +$450K ﹤0.01% 1964
2025
Q3 		$733K Buy
42,449
+23
+0.1% +$283 ﹤0.01% 1966
2025
Q2 		$398K Buy
42,426
+30,634
+260% +$252K ﹤0.01% 2098
2025
Q1 		$83.8K Sell
11,792
-590
-5% -$5.96K ﹤0.01% 2327
2024
Q4 		$144K Sell
12,382
-272
-2% -$4.25K ﹤0.01% 2288
2024
Q3 		$260K Buy
12,654
+429
+4% +$9.89K ﹤0.01% 2162
2024
Q2 		$274K Sell
12,225
-174
-1% -$4.14K ﹤0.01% 2123
2024
Q1 		$341K Buy
12,399
+567
+5% +$15.7K ﹤0.01% 2083
2023
Q4 		$361K Sell
11,832
-15,484
-57% -$445K ﹤0.01% 2080
2023
Q3 		$864K Buy
27,316
+470
+2% +$18.2K ﹤0.01% 1731
2023
Q2 		$1.09M Sell
26,846
-210
-0.8% -$8.52K ﹤0.01% 1622
2023
Q1 		$1.01M Buy
27,056
+1,761
+7% +$69.1K ﹤0.01% 1689
2022
Q4 		$883K Sell
25,295
-533
-2% -$25.3K ﹤0.01% 1800
2022
Q3 		$1.45M Sell
25,828
-2,437
-9% -$151K ﹤0.01% 1563
2022
Q2 		$1.46M Sell
28,265
-559,666
-95% -$28.4M ﹤0.01% 1578
2022
Q1 		$42M Sell
587,931
-39,566
-6% -$3.35M 0.04% 594
2021
Q4 		$74.2M Sell
627,497
-141,959
-18% -$17.8M 0.07% 394
2021
Q3 		$103M Buy
769,456
+375,933
+96% +$56.9M 0.1% 259
2021
Q2 		$63.7M Buy
393,523
+353,428
+881% +$27.5M 0.06% 454
2021
Q1 		$3.22M Buy
40,095
+4,503
+13% +$302K ﹤0.01% 1496
2020
Q4 		$1.94M Sell
35,592
-1,793
-5% -$65.1K ﹤0.01% 1524
2020
Q3 		$743K Buy
+37,385
New +$780K ﹤0.01% 1826
2020
Q2 		– Sell
-5,423
Closed -$66K – 3007
2020
Q1 		$66K Sell
5,423
-3,091
-36% -$41.6K ﹤0.01% 2437
2019
Q4 		$125K Buy
8,514
+3,493
+70% +$48.6K ﹤0.01% 2469
2019
Q3 		$67K Buy
+5,021
New +$80.1K ﹤0.01% 2569

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Victory Capital Management's NTLA Position: Q2 2026 in Review

Victory Capital Management reduced its Intellia Therapeutics (NTLA) stake by 76% in Q2 2026, selling an estimated $661K and leaving 15,291 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #2205.

Victory Capital Management first reported a position in NTLA in Q3 2019 and has held it in 27 quarters since. The position peaked at $103M in Q3 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Victory Capital Management held 15,291 shares of Intellia Therapeutics worth $259K as of Q2 2026.
  • Victory Capital Management sold 47,218 Intellia Therapeutics shares in Q2 2026, an estimated $661K.
  • Intellia Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2205 holding.
  • Victory Capital Management first reported a position in Intellia Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Victory Capital Management's Intellia Therapeutics position peaked at $103M in Q3 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.